ChromaDex Corporation

ChromaDex Corporation is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. ChromaDex Corporation has good growth characteristics. ChromaDex Corporation is not very popular among insiders. ChromaDex Corporation is a good stock to invest in, but there are better stocks to choose.
Log in to see more information.
Chromadex Corp. is a nutraceutical company, which engages in acquiring, developing, and commercializ...
CDXC Fundamental Data by TradingView

News

ChromaDex expands pharmaceutical-grade Niagen IV, injection offerings
ChromaDex expands pharmaceutical-grade Niagen IV, injection offerings

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

ChromaDex Announces Expansion of Pharmaceutical-Grade Niagen IV and Injection Offerings to Additional Leading Wellness Clinics
ChromaDex Announces Expansion of Pharmaceutical-Grade Niagen IV and Injection Offerings to Additional Leading Wellness Clinics

Business Wire ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, is excited to announce the second wave of intravenous (IV...\n more…

ChromaDex Celebrates 25 Years of Innovation and Pioneering NAD+ Research for Healthy Aging Solutions
ChromaDex Celebrates 25 Years of Innovation and Pioneering NAD+ Research for Healthy Aging Solutions

Business Wire ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, proudly announces its 25th anniversary. For a quarter of a...\n more…

Crestwood Advisors Group LLC Trims Position in ChromaDex Co. (NASDAQ:CDXC)
Crestwood Advisors Group LLC Trims Position in ChromaDex Co. (NASDAQ:CDXC)

Zolmax Crestwood Advisors Group LLC cut its position in ChromaDex Co. (NASDAQ:CDXC - Free Report) by 45.1% in the second quarter, according to the company in its most recent disclosure with the Securities...\n more…

Crestwood Advisors Group LLC Reduces Position in ChromaDex Co. (NASDAQ:CDXC)
Crestwood Advisors Group LLC Reduces Position in ChromaDex Co. (NASDAQ:CDXC)

Ticker Report Crestwood Advisors Group LLC lessened its stake in shares of ChromaDex Co. (NASDAQ:CDXC - Free Report) by 45.1% during the 2nd quarter, according to the company in its most recent filing with the...\n more…

ChromaDex to Participate in Renmarks Virtual Non-Deal Roadshow Series On Thursday, August 29, 2024
ChromaDex to Participate in Renmarks Virtual Non-Deal Roadshow Series On Thursday, August 29, 2024

Business Wire ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announced today that they will be participating in Renmark...\n more…